ICC / CEMTRO Cell (high-density ACI)

Same lineage as MACI — cultured autologous chondrocytes on a collagen membrane — with one variable changed: cell density. Instant Cemtrocell (ICC), developed at Clínica CEMTRO in Madrid, implants about 5 million cells per cm², roughly five times conventional ACI dosing. The premise: more cells should yield repair tissue closer to hyaline cartilage, with more type II collagen and aggrecan.

Where the premise comes from

A sheep study — 15 animals — by the same group. Implantation of 5 million cells produced more hyaline-like, less variable repair tissue than 1 million cells, with higher type II collagen and aggrecan expression, and outperformed mesenchymal-cell treatments histologically. This is the load-bearing evidence for the high-density idea. It does not establish human efficacy, let alone superiority over commercial MACI.

The human evidence

All of it comes from Clínica CEMTRO, and all of it is uncontrolled:

• Knee, 50 patients: at 24 months, mean IKDC improved about 31 points, with significant reductions in pain and swelling.
• Ankle (talus), 24 patients: at 24 months, median pain score fell from 8 to 2 and AOFAS rose from 39.5 to 90; biopsies showed hyaline-like matrix with viable chondrocytes.
• Knee with vs without ACL reconstruction, 48 patients: both groups improved substantially at 24 months (pain ~8 to ~2; IKDC ~37 to ~75), with 71–90% returning to pre-injury activity; concurrent ACL reconstruction did not worsen results.

These magnitudes are in the same range as MACI case series — which is the honest point. Nothing published shows high density beats standard density in humans, because no such comparison has been run.

What is missing

The list is short because the literature is short. There is no randomized — or even non-randomized controlled — human study against standard MACI or any comparator. There is no multicenter replication and no published follow-up beyond 24 months in the knee series. All human papers share authors with the entity commercializing the procedure, with the usual risk of selection and reporting bias, and sample sizes are small (24–50 patients). The wider ACI literature offers the cautionary tale: early uncontrolled gains do not guarantee long-term superiority — first-generation ACI looked good in series and then matched microfracture at 14–15 years in a randomized trial.

Practical notes

The patient experience mirrors MACI: arthroscopic biopsy, cell culture, a second-stage implantation, and comparable rehab. Availability is essentially one center, in Madrid — patients travel for it and often pay out of pocket. It is not FDA-approved; it operates under European/Spanish advanced-therapy provisions.

Questions for your surgeon (or the clinic)

• Where is the published follow-up beyond 24 months?
• Has any study — anywhere — compared this against standard MACI?
• What exactly would I be paying for over MACI, given that no human data show the higher density does more?
• What is the revision plan, and who handles complications once I am back home?

Safety

Presumably similar to MACI: two-stage surgery with your own cultured cells, so no immune rejection risk and no donor site. The published series report no major safety signals, but small uncontrolled series cannot exclude uncommon harms. The single most important missing study — a comparative trial of high-density versus standard ACI — has, as far as we could verify, not even been registered.